Your Donations in Action: Johanna Ospel, MD, PhD
Advancing imaging-based stroke outcome assessment
Clinical trials of acute ischemic stroke treatments commonly assess outcomes using measures such as the 90-day modified Rankin Scale. Although essential, these measures can be time- and labor-intensive and may not capture small but clinically meaningful changes in a patient’s recovery.
Imaging markers could offer an earlier, more sensitive way to measure treatment effects, but their use as surrogate endpoints remains limited. Researchers have not yet established which imaging features are most closely associated with meaningful patient outcomes.
For her 2024 RSNA Research Fellow Grant project, “Validating Advanced Imaging Assessment for Stroke Outcome Prediction (AI-STROKE),” Johanna Ospel, MD, PhD, clinical associate professor in the Department of Radiology at the University of Calgary in Alberta, Canada, and colleagues examined associations between post-thrombectomy imaging findings and patients’ subsequent clinical outcomes.
AI-STROKE is an imaging sub-study of ESCAPE-CORE, a prospective study using serial MRI examinations in patients with anterior circulation large vessel occlusion who undergo thrombectomy. The researchers are examining associations between post-thrombectomy imaging findings and patients’ subsequent functional, neurological, cognitive and quality-of-life outcomes.
While enrollment in ESCAPE-CORE remains ongoing, the researchers have advanced the project through analyses of completed multicenter imaging datasets and continued development of the methods that will be applied to ESCAPE-CORE data.
They identified infarct growth rate as a reproducible imaging marker associated with clinical outcomes. Their analyses also showed that measurements derived from noncontrast CT, multiphase CT angiography and CT perfusion may offer practical alternatives to MRI-based measurements, potentially extending the approach to sites with different imaging capabilities.
“If validated, these imaging markers could allow clinicians and researchers to assess treatment effects much earlier and more sensitively than current crude clinical outcome scales,” Dr. Ospel said. “They could improve prognostication after stroke and potentially make future clinical trials faster, smaller and less costly by providing validated imaging-based outcome measures.”
The R&E Foundation grant was Dr. Ospel’s first award as a principal investigator and helped lay the groundwork for her career as a clinician-scientist. It was also a critical first step toward securing additional funding to put toward a substudy on the combined value of imaging and blood-based biomarkers.
“The grant was the foundation for building my neurovascular research program, for which I was able to raise over $2 million in funding,” Dr. Ospel said.
For More Information
Learn more about R&E Foundation funding opportunities.
Read our previous Your Donations in Action story.